Search research articles
Contact Us
Filters
Showing results (121-130 of 176) with videos related to
Page
of 18
Sort By:
The Lancet. Oncology
|
June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Clinical Genitourinary Cancer
|
November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
Yung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
Clinical Genitourinary Cancer
|
October 8, 2018
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, et al.
British Journal of Clinical Pharmacology
|
August 1, 2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours
Darcy B Pooler, Dylan B Ness, John Sarantopoulos, et al.
Targeted Oncology
|
January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
Mhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
JCO Precision Oncology
|
September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Irene Tsung, David C Smith, Elisabeth I Heath, et al.
JAMA Oncology
|
August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial
Sumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
European Urology
|
August 28, 2020
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma
Yung Lyou, Petros Grivas, Jonathan E Rosenberg, et al.
British Journal of Cancer
|
December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
European Urology
|
April 6, 2024
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
Robert J Motzer, Toni K Choueiri, Thomas Hutson, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 176) with videos related to
Sort By:
Page
of 18
The Lancet. Oncology
|
June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
Clinical Genitourinary Cancer
|
November 16, 2021
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
Yung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, et al.
Clinical Genitourinary Cancer
|
October 8, 2018
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, et al.
British Journal of Clinical Pharmacology
|
August 1, 2020
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours
Darcy B Pooler, Dylan B Ness, John Sarantopoulos, et al.
Targeted Oncology
|
January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
Mhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
JCO Precision Oncology
|
September 16, 2025
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Irene Tsung, David C Smith, Elisabeth I Heath, et al.
JAMA Oncology
|
August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial
Sumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
European Urology
|
August 28, 2020
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma
Yung Lyou, Petros Grivas, Jonathan E Rosenberg, et al.
British Journal of Cancer
|
December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
European Urology
|
April 6, 2024
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
Robert J Motzer, Toni K Choueiri, Thomas Hutson, et al.
Page
of 18